Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds

Summary

Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without aura. 2. The secondary objectives are to determine: 1. The safety and tolerability of Cambia from a single dose 2. Three-month safety evaluation of Cambia in outpatient usage in this population

Timeline

Start

2015-01

Primary completion

2016-02

Completion

2016-02

Drugs

Indications